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Abstract
Background—Geleophysic dysplasia (GD, OMIM 231050) is an autosomal recessive disorder 
characterized by short stature, small hands and feet, stiff joints, and thick skin. Patients often 
present with a progressive cardiac valvular disease which can lead to an early death. In a previous 
study including six GD families, we have mapped the disease gene on chromosome 9q34.2 and 
identified mutations in the A Disintegrin And Metalloproteinase with Thrombospondin repeats-
like 2gene (ADAMTSL2).
Competing interests None
Patient consent Obtained
Ethics approval This study was conducted with the approval of the Necker Hospital.
Provenance and peer review Not commissioned; externally peer reviewed.
HHS Public Access
Author manuscript
J Med Genet. Author manuscript; available in PMC 2015 April 29.
Published in final edited form as:
J Med Genet. 2011 June ; 48(6): 417–421. doi:10.1136/jmg.2010.087544.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Methods—Following this study, we have collected the samples of 30 additional GD families, 
including 33 patients and identified ADAMTSL2 mutations in 14/33 patients, comprising 13 novel 
mutations. The absence of mutation in 19 patients prompted us to compare the two groups of GD 
patients, namely group 1, patients with ADAMTSL2 mutations (n¼20, also including the 6 patients 
from our previous study), and group 2, patients without ADAMTSL2 mutations (n¼19).
Results—The main discriminating features were facial dysmorphism and tip-toe walking, which 
were almost constantly observed in group 1. No differences were found concerning heart 
involvement, skin thickness, recurrent respiratory and ear infections, bronchopulmonary 
insufficiency, laryngo-tracheal stenosis, deafness, and radiographic features.
Conclusions—It is concluded that GD is a genetically heterogeneous condition. Ongoing 
studies will hopefully lead to the identification of another disease gene.
INTRODUCTION
Geleophysic dysplasia (GD, OMIM 231050) is a rare autosomal recessive disorder 
characterized by short stature, small hands and feet, stiff joints, thick skin, and pseudo-
muscular hypertrophy.1 Facial features include round full ‘happy’ face (from the Greek 
geleos: ‘happy’ and physis: ‘nature’), small nose with anteverted nostrils, long flat philtrum, 
long thin upper lip, broad nasal bridge, and narrow palpebral fissures. The radiological 
manifestations include brachymetacarpy/tarsy, delayed bone age, cone shaped epiphyses, 
shortened long tubular bones, and vertebral abnormalities (ovoid vertebral bodies, 
platyspondyly) (figure 1).
Patients often present with a progressive cardiac valvular disease, which may result in 
secondary hypertrophy and cardiac failure leading to death in the first years of life.2 
Progressive hepatomegaly, recurrent respiratory infections and tracheal stenosis leading to 
severe respiratory problems are also commonly observed.
GD belongs to the group of acromelic dysplasias (group 14 of the International 
Classification of Genetic Skeletal Disorders3) which also includes acromicric dysplasia 
(AD) and WeilleMarchesani syndrome.
AD4 is distinct from GD by the absence of cardiac valvular disease, the presence of distinct 
xray abnormalities (internal notch of the femoral head, internal notch of the second 
metacarpal, and external notch of the fifth metacarpal) and autosomal dominant mode of 
inheritance. The molecular bases remain unknown.5
WeilleMarchesani syndrome is characterized by ectopia lentis and microspherophakia and is 
either due to FBN1 mutations, responsible for the dominant form,6 or ADAMTS10 
mutations, responsible for the autosomal recessive form.7
Studying a series of six GD families, we have mapped the disease gene on chromosome 
9q34.2 and identified four distinct missense mutations and a nonsense mutation in the A 
Disintegrin And Metalloproteinase with Thrombospondin repeats-like 2 gene 
(ADAMTSL2). We also identified Latent TGFb Binding Protein 1 (LTBP1) as a partner of 
ADAMTSL2 and found an enhanced transforming growth factor β (TGFβ) signalling in GD 
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fibroblasts, suggesting a role for ADAMTSL2 in the regulation of the bioavailability of 
TGFβ.8
We present here ADAMTSL2 molecular screening in a series of 33 additional GD cases. The 
absence of mutation in a significant number of patients prompted us to compare the clinical 
and radiological features of mutated and non-mutated patients.
METHODS
Patients
Diagnosis of GD was assessed by a clinical geneticist. All patients included in the study 
fulfilled the diagnosis criteria for GD: (1) short stature (≤2 SD); (2) short hands and feet; (3) 
stiff joints; and (4) dysmorphic features. Cardiac valvular disease and thickened skin were 
not considered as mandatory criteria as these features were not present in 3/6 of our initial 
series.8 Skeletal survey on all patients were requested to exclude features of acromicric 
dysplasia, specifically internal notch of the femoral head or of the second metacarpal and 
external notch of the fifth metacarpal.
Eleven patients were included in the study through the French reference center for 
constitutional bone disorders in Necker Hospital and 22 patients were diagnosed as GD by 
clinical geneticists from various countries (Belgium, UK, Germany, Netherland, Lebanon, 
Portugal, and Turkey). A total of 33 patients were included (21 males and 12 females), 
ranging in age from 2 months to 26 years and originating from Algeria, Canada, China, 
England, Italy, Japan, Lebanon, Morocco, Pakistan, Portugal, Russia, and Turkey. Five 
patients were offspring of consanguineous relationships (patient 5, 17, 21, 22, and 24); there 
was one sib pair (patient 32 and 33) and three cousins (patient 17, 21 and 24). Appropriate 
written informed consents regarding human study were obtained from all subjects.
Mutation analysis
ADAMTSL2 exon and flanking intron sequences were amplified from patient DNA by PCR 
using 21 couples of primers designed with the Primer 3 software. The amplicons were 
purified and sequenced using the BigDye Terminator Cycle Sequencing Kit v3.1 (Applied 
Biosystems, Foster City, California, USA) on an automatic sequencer (ABI 3100).
Statistical analyses
A non-parametric ManneWhitney test was used to compare means and a χ2 test was used to 
compare ratios in the two patients groups.
RESULTS
ADAMTSL2 sequence analysis performed in the 33 patients allowed us to identify 14 distinct 
mutations in 14 patients comprising 13 novel mutations (table 1). Mutations were present at 
the homozygous state in five cases while patients were compound heterozygous in six other 
cases. In three cases (4, 7, and 15) only a single heterozygous mutation, inherited from the 
mother, was detected.
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The mutations were located throughout the gene (figure 2). Among them, one mutation was 
a nonsense mutation (p.[R425X]), one was a 30 bp deletion affecting the N glycanrich 
module (c.[1148_1177del]), and 11 were missense mutations (p.[W50C], p.[R72Q], p.
[E114K], p.[R159W], p.[A165T], p.[C171R], p.[R221C], p.[A239T], p.[R593C], p.[S635L] 
and p.[P906L]). We also identified the p.[C407C] mutation which was predicted to alter 
splicing but mRNA was not available for this patient. Except for p.[E114K], none of these 
mutations had been previously described. All mutations cosegregated with the disease and 
were not identified in 200 control chromosomes. The missense mutations consistently 
involved residues conserved across species and across the ADAMTSL family members. The 
prediction program PolyPhen was queried for the reported missense mutations and all of 
them were predicted to have a damaging role.
The absence of mutation in 19/33 patients (58%) prompted us to compare the clinical and 
radiological features of the two groups of GD patients (table 2), namely group 1, patients 
with ADAMTSL2 mutations (n¼20, also including the six patients from our initial study8), 
and group 2, patients without ADAMTSL2 mutation (n¼19). Importantly, blinded 
comparison was made by clinical geneticists unaware of the molecular diagnosis.
No consanguinity was found in group 2 whereas half of the families of group 1 were 
consanguineous. Antenatal history showed polyhydramnios and prenatal growth retardation 
in 91% and 76% of group 1 patients, versus 18% and 31% of group 2 patients, respectively. 
Birth term was 2 weeks earlier in group 1 (because of a higher proportion of induced 
deliveries due to prenatal growth retardation) and birth head circumference was normal for 
the term in both groups. The mean height was lower than _4 SD in both groups, but short 
stature was more severe in group 2 (_5.8 vs _4.1 SD). Tip-toe walking (restriction of 
dorsiflexion of the feet as a consequence of the extreme joint limitations and contractures) 
was almost constantly observed in group 1 whereas it was rarely reported in group 2 (88% 
vs 18%). Concerning facial dysmorphism, thin upper lip, long flat philtrum, and narrow 
palpebral fissures were much more frequent in group 1 than in group 2 (figure 3). No 
significant difference was found concerning heart involvement and skin thickness (which 
were observed in approximately 70% of both groups), recurrent respiratory and ear 
infections, bronchopulmonary insufficiency, laryngotracheal stenosis, high pitched voice, 
hepatomegaly, ophthalmologic symptoms, deafness, and radiographic features (delayed 
bone age, cone shaped epiphyses, shortened long tubular bones, abnormal femoral heads, 
platyspondyly, and ovoid vertebral bodies). One patient from group 1 had a severe systemic 
hypertension. However, the long term follow-up of patients from both groups did not reveal 
any difference in the course of the disease. Two mutated patients and five nonmutated 
patients died of cardiorespiratory failure (mean age 3.6 years).
DISCUSSION
We report here the identification of 14 ADAMTSL2 mutations in 14/33 GD patients (42%), 
comprising 13 novel mutations located throughout the gene, with a majority of missense 
mutations involving highly conserved residues.
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The absence of identified mutations in 58% of GD patients may have different explanations. 
First, only direct sequencing of ADAMTSL2 was performed. One cannot exclude partial 
intragenic deletions or mutations in the introns or promoter region. This is probably the case 
for at least three patients (4, 7, and 15) where only a single heterozygous mutation was 
detected. However, the limit of our screening probably does not account for such a high 
proportion (58%) of non-mutated patients.
The absence of an identified mutation could be also due to overlapping diagnosis. Indeed 
GD is closely related to AD, which is the main differential diagnosis, and the distinction can 
be difficult especially in the absence of cardiac valvular disease.9 Importantly, recurrent sibs 
or consanguineous parents were never observed in the non-mutated patients group. 
However, all patients fulfilled the diagnosis criteria for GD and at least nine non-mutated 
patients presented with characteristic valvular cardiac disease.
Finally, we did not find any significant difference in the main clinical and radiological 
features characteristic of GD, namely cardiorespiratory involvement, skin thickness, 
laryngeal stenosis, hepatomegaly, natural history of the disorder, and severe outcome. By 
contrast, we found minor discriminating features including facial dysmorphism (thin upper 
lip, long flat philtrum and narrow palpebral fissures) and tip-toe walking, only consistently 
observed in the ADAMTSL2 mutated group.
Our study supports the proposal that GD is a genetically heterogeneous condition, with 
ADAMTSL2 mutations being identified in 42% of GD patients. Ongoing studies will 
hopefully lead to the identification of another GD gene presumably also involved in TGFβ 
bioavailability.
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Figure 1. 
Skeletal manifestations of geleophysic dysplasia. (A) Hand x-rays of patient 3 at age 3 years 
(top) and age 10 years (bottom). Note the very small hand with short and plump tubular 
bones and cone shaped epiphyses. Note also the carpal ossification delay. (B) Hip and lower 
limbs x-ray of patient 4 at age 8 months. Note the small capital femoral epiphyses and the 
shortened long tubular bones. (C) Anteroposterior view of the spine of patient 12 at age 1 
year. Note the ovoid vertebral bodies.
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Figure 2. 
ADAMTSL2 mutations. In italics: ADAMTSL2 mutations previously identified (Le Goff et 
al8). In non-italics: novel mutations.
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Figure 3. 
Clinical manifestations of geleophysic dysplasia in patient 28 (mutated in ADAMTSL2) and 
patient 31 (not mutated in ADAMTSL2). (A, E) Note the short stature, small hands and feet, 
stiff joints and pseudomuscular hypertrophy (patient 28 at age 9 years and patient 31 at age 
4 years). (B, F, G) Note the very small hands and feet. (C) Note the tip-toe walking. (D, H) 
Note the common facial features, including round full face, small nose with anteverted 
nostrils and long philtrum (patient 28 at age 6 years and patient 31 at age 4 years). Note also 
the thin upper lip, and narrow palpebral fissures present only in patient 28 (mutated in 
ADAMTSL2). Informed consent was obtained to publish the photographs in this figure.
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Table 2
Comparison of geleophysic dysplasia (GD) patients with ADAMTSL2 mutations (group 1) and without 
ADAMTSL2 mutation (group 2)
Group 1: mutated (n=20) Group 2: non- mutated (n=19) p Value
Consanguinity 10/20 0/16 0.003
Polyhydramnios 10/11 2/11 0.003
Prenatal growth retardation 13/17 4/13 0.03
Birth term (weeks of amenorrhoea) 37.5±2.1 (3 NA) 39.7±1.1 (5 NA) 0.004
Birth length (cm) 44.6±3.0 (5 NA) 48.9±1.6 (8 NA) 0.0004
Birth head circumference (cm) 33.5±1.7 (4 NA) 35.7±1.1 (11 NA) 0.002
Cardiac valvular anomaly 14/18 9/13 0.89
Pulmonary arterial hypertension 4/11 5/9 0.42
Cardiac surgery 3/14 4/9 0.47
Recurrent respiratory and ear infections 8/12 8/15 0.75
Bronchopulmonary insufficiency 8/16 7/15 0.62
Laryngotracheal stenosis 6/13 7/14 0.99
Deceased (of cardiorespiratory failure) 2/20 5/19 0.36
Deafness 8/13 6/13 0.69
Ophthalmologic symptoms 8/13 3/12 0.15
Mild mental retardation 6/15 5/17 0.80
Height (SD) −4.1±1.0 (6 NA) −5.8±2.4 (3 NA) 0.016
Head circumference (SD) −0.9±1.7 (11 NA) 0.0±1.2 (5 NA) 0.15
Tip-toe walking 14/16 2/11 0.001
Thickened skin 10/15 9/13 0.99
Pseudomuscular hypertrophy 11/14 7/14 0.24
Hepatomegaly 5/17 9/16 0.22
High pitch voice 6/11 1/7 0.22
Round full face 14/15 9/16 0.05
Small nose 11/16 13/15 0.41
Broad nasal bridge 14/15 11/15 0.33
Long flat philtrum 18/19 10/17 0.027
Thin upper lip 18/18 6/15 0.005
Narrow palpebral fissures 13/15 7/17 0.03
Delayed bone age 12/13 12/13 0.99
Cone shaped epiphyses 5/8 8/12 0.99
Shortened long tubular bones 15/15 9/11 0.33
Small and/or irregular femoral epiphyses 8/10 6/12 0.31
Platyspondyly 5/8 2/9 0.22
Ovoid vertebral bodies 6/10 7/11 0.99
NA, not available.
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